Author:
Zhou Qiang,Peng Rui-Qing,Wu Xiao-Jun,Xia Qing,Hou Jing-Hui,Ding Ya,Zhou Qi-Ming,Zhang Xing,Pang Zhi-Zhong,Wan De-Sen,Zeng Yi-Xin,Zhang Xiao-Shi
Abstract
Abstract
Background
Although an abundance of evidence has indicated that tumor-associated macrophages (TAMs) are associated with a favorable prognosis in patients with colon cancer, it is still unknown how TAMs exert a protective effect. This study examined whether TAMs are involved in hepatic metastasis of colon cancer.
Materials and methods
One hundred and sixty cases of pathologically-confirmed specimens were obtained from colon carcinoma patients with TNM stage IIIB and IV between January 1997 and July 2004 at the Cancer Center of Sun Yat-Sen University. The density of macrophages in the invasive front (CD68TFHotspot) was scored with an immunohistochemical assay. The relationship between the CD68TFHotspot and the clinicopathologic parameters, the potential of hepatic metastasis, and the 5-year survival rate were analyzed.
Results
TAMs were associated with the incidence of hepatic metastasis and the 5-year survival rate in patients with colon cancers. Both univariate and multivariate analyses revealed that the CD68TFHotspot was independently prognostic of survival. A higher 5-year survival rate among patients with stage IIIB after radical resection occurred in patients with a higher macrophage infiltration in the invasive front (81.0%) than in those with a lower macrophage infiltration (48.6%). Most importantly, the CD68TFHotspot was associated with both the potential of hepatic metastasis and the interval between colon resection and the occurrence of hepatic metastasis.
Conclusion
This study showed evidence that TAMs infiltrated in the invasive front are associated with improvement in both hepatic metastasis and overall survival in colon cancer, implying that TAMs have protective potential in colon cancers and might serve as a novel therapeutic target.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference70 articles.
1. Mayo SC, Pawlik TM: Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol. 2009, 3 (2): 131-144. 10.1586/egh.09.8.
2. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007, 43 (9): 1348-1360. 10.1016/j.ejca.2007.03.021.
3. Shah A, Alberts S, Adam R: Accomplishments in 2007 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res. 2008, 2 (3 Suppl): S13-18.
4. Shrivastav A, Varma S, Saxena A, DeCoteau J, Sharma RK: N-myristoyltransferase: a potential novel diagnostic marker for colon cancer. J Transl Med. 2007, 5: 58-10.1186/1479-5876-5-58.
5. Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, Kallioniemi A, Meling GI, Skotheim RI, Rognum TO, Thiis-Evensen E, Lothe RA: Hypermethylated MAL gene - a silent marker of early colon tumorigenesis. J Transl Med. 2008, 6: 13-10.1186/1479-5876-6-13.
Cited by
161 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献